Status:
COMPLETED
Hyaluronidase Via LADD Scleroderma-induced Microstomia
Lead Sponsor:
University of Nebraska
Conditions:
Microstomia
Scleroderma
Eligibility:
All Genders
19+ years
Phase:
EARLY_PHASE1
Brief Summary
Two treatment methods, ablative carbon dioxide (CO2) laser and intradermal hyaluronidase, will be combined to maximize the beneficial potential of each. Laser-assisted drug delivery (LADD) has been sh...
Detailed Description
In this study, the investigator will combine two treatment modalities, ablative carbon dioxide (CO2) laser, and intradermal hyaluronidase, via laser-assisted drug delivery. The goal is to maximize the...
Eligibility Criteria
Inclusion
- Patient at the Lauritzen Outpatient Clinic or Westroads Clinic, Dept Dermatology
- Diagnosed with scleroderma-induced microstomia
- Capable and willing to participate
- Free of medical conditions that will interfere with successful completion of the study, such as severe dementia or seizure disorder
- Aged 19 or older
Exclusion
- Pregnant and breastfeeding women
- 18 years old or younger
- Infections or inflammation in or near the area of treatment
- Prior treatment with hyaluronidase, LADD or ablative CO2 laser treatment, or a history of adverse reactions to the treatments
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 24 2024
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT05995626
Start Date
March 1 2024
End Date
September 24 2024
Last Update
April 13 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Nebraska Medical Center, Lauritzen Outpatient Center
Omaha, Nebraska, United States, 68105
2
Nebraska Medicine, Dermatology Westroads
Omaha, Nebraska, United States, 68114